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Background
Cancer cachexia remains a major clinical problem with the
majority of advanced cancer patients suffering from
aspects of this complex syndrome. Two key features of
cancer cachexia include anorexia and an acute phase
response, both of which contribute directly to accelerated
wasting. Some of the metabolic abnormalities in cancer
cachexia are similar to those involved in trauma and sepsis
and involve a systemic inflammatory response with pro-
found alterations in liver metabolism, together with loss of
lean body mass. Such depletion of lean tissue (principally
skeletal muscle) is an important factor contributing to the
decreased survival of cancer patients. Skeletal muscle is
the main labile source of amino acids in the body and this
muscle is broken down to provide amino acids to the liver
for the continuing, relentless acute phase response which
is a feature of cancer cachexia.
A novel 24kDa, heavily glycosylated, cachectic factor
which can trigger muscle proteolysis during the process
of cancer cachexia was identified first from a cachexia-
inducing mouse tumor [1] and from the urine of patients
with pancreatic carcinoma and weight-loss [2]. The factor
was identified as being a product of the human cachexia
associated protein (HCAP) gene [3] and was later
referred to as proteolysis inducing factor (PIF) which had
a small core peptide (PIF-CP) of less than 3kDa and was
extensively glycosylated. This glycosylated factor was
shown by us to drive the acute phase response and to
induce an inflammatory response from human hepato-
cytes [4] and other cell types [5,6].
The story then became more complex. From work in
an unrelated area, a peptide was identified as a neuronal
survival peptide (YP-30) in rat neuronal cells subjected to
oxidative stress [7] and this peptide proved to be identical
in sequence to the PIF-CP. The rat gene encoding the
YP-30 peptide was cloned and named the DSEP gene [8].
Around the same time, and again in a completely unre-
lated area, a group in Tubingen, working on skin antibio-
tics, identified and cloned the dermcidin (DCD) gene [9]
which produced the dermcidin antibiotic peptide DCD-1.
The HCAP, DSEP and DCD genes are completely homo-
logous. In a bizarre twist of biological fate this gene
encodes different products derived from separate regions
of the gene. One product is the 30 amino acid core pep-
tide of proteolysis inducing factor (PIF-CP), which is
identical to the YP-30 neuronal survival peptide, and an
entirely separate product, the dermcidin antibiotic pep-
tide DCD-1. In a further, unrelated area, the DCD gene
was identified as a candidate oncogene in invasive breast
cancer [10]. We later went on to demonstrate that the
DCD gene encoding PIF-CP, YP-30 and DCD-1 could
protect various tumour cells from oxidative stress and
hypoxia [11,12] and that the portion of the gene respon-
sible for this protection was that encoding the PIF-CP/
YP-30 peptide [13]. Expression of the gene also appeared
to confer a proliferative effect on cells.
Aims
The aim of this paper is to describe the biology of the
dermcidin gene and to identify the portion of the gene
responsible for inducing cell proliferation.
Results and conclusion
In this study, we confirm a proliferative effect of DCD
overexpression in the HuH7 human hepatic cell line.
The proliferation is abrogated by prevention of PIF-CP
translation or inactivation of its calcineurin-like phos-
phatase domain by site-directed mutagenesis. Prevention
of translation of the DCD-1 antibiotic peptide had no
effect. Treatment of cells with a 30 amino acid synthetic
PIF-CP induced an increase in proliferation. Pathway
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analysis revealed several gene networks involved in the
cellular response to the peptide, one with VEGFB as a
hub and two other networks converging on Fos and
Myc.
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